CYTK – cytokinetics, incorporated (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

CYTK

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/19

07:08 pm

cytk

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms [Yahoo! Finance]

Low Report

Report

12/19

04:00 pm

cytk

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Low Report

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Report

12/19

11:24 am

cytk

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? [Yahoo! Finance]

Low Report

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? [Yahoo! Finance]

Report

12/19

08:27 am

cytk

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Low Report

Report

12/18

08:02 am

cytk

Cytokinetics (NASDAQ:CYTK) was given a new $95.00 price target on by analysts at The Goldman Sachs Group, Inc..

Low Report

Cytokinetics (NASDAQ:CYTK) was given a new $95.00 price target on by analysts at The Goldman Sachs Group, Inc..

Report

12/18

07:11 am

cytk

Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.

Low Report

Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.

Report

12/17

07:30 am

cytk

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Medium Report

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Report

12/16

04:00 pm

cytk

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Medium Report

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Report

12/16

08:40 am

cytk

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf

Low Report

Report

12/12

02:37 pm

cytk

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Low Report

Report

12/12

08:42 am

cytk

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Medium Report

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Report

12/12

08:06 am

cytk

Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.

Medium Report

Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.

Report

12/9

09:18 am

cytk

Notice For Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf

Medium Report

Report

12/8

08:35 am

cytk

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Low Report

Report

12/4

12:05 pm

cytk

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Low Report

Report

12/2

12:39 pm

cytk

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims o

Low Report

Report

12/1

11:06 am

cytk

Cytokinetics (NASDAQ:CYTK) had its "neutral" rating reaffirmed by analysts at UBS Group AG.

Low Report

Cytokinetics (NASDAQ:CYTK) had its "neutral" rating reaffirmed by analysts at UBS Group AG.

Report

12/1

08:44 am

cytk

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf

Low Report

Report

11/26

10:46 am

cytk

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Inspire Medical Systems, Inc. (NYSE: INSP); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on

Low Report

Report

11/24

08:43 am

cytk

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and Stride, Inc. (NYSE: LRN): Grabar Law Office is Investigating Claims on Your Behalf

Low Report

Report

11/21

03:32 pm

cytk

Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling [Seeking Alpha]

Low Report

Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling [Seeking Alpha]

Report

11/19

02:55 pm

cytk

Renowned Neuromuscular Expert Will Head New NYU Langone ALS Center [Yahoo! Finance]

Low Report

Renowned Neuromuscular Expert Will Head New NYU Langone ALS Center [Yahoo! Finance]

Report

11/19

07:40 am

cytk

Cytokinetics: A Heavily Mispriced Cardiovascular Platform [Seeking Alpha]

Low Report

Cytokinetics: A Heavily Mispriced Cardiovascular Platform [Seeking Alpha]

Report

11/18

04:00 pm

cytk

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Low Report

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Report

11/18

06:19 am

cytk

Expanded Effort Will Help Standardize, Improve Care for Hypertrophic Cardiomyopathy [Yahoo! Finance]

Low Report

Expanded Effort Will Help Standardize, Improve Care for Hypertrophic Cardiomyopathy [Yahoo! Finance]

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.